**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 65546

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Fecal metabolomic profiles: A comparative study of patients with colorectal cancer *vs* adenomatous polyps**

Nannini G *et al*. Comparative study of fecal metabolomic profiles

Giulia Nannini, Gaia Meoni, Leonardo Tenori, Maria Novella Ringressi, Antonio Taddei, Elena Niccolai, Simone Baldi, Edda Russo, Claudio Luchinat, Amedeo Amedei

**Giulia Nannini, Maria Novella Ringressi, Antonio Taddei, Elena Niccolai, Simone Baldi, Edda Russo, Amedeo Amedei,** Department of Clinical and Experimental Medicine, University of Florence, Florence 50134, Italy

**Gaia Meoni, Leonardo Tenori,** Department of Chemistry “Ugo Schiff”, University of Florence, Florence 50134, Italy

**Claudio Luchinat,** Department of Chemistry & Magnetic Resonance Center (CERM), University of Florence, Florence 50134, Italy

**Author contributions:** Nannini G and Meoni G equally contributed to drafting the manuscript; Nannini G, Meoni G, Tenori L, Luchinat C, and Amedei A designed and coordinated the study; Nannini G and Meoni G performed the research; Niccolai E, Ringressi MN, and Taddei A contributed to providing patients’ clinical information; Niccolai E, Baldi S, and Russo E collected the biological samples; Meoni G and Tenori L analyzed the data; Luchinat C and Amedei A coordinated the research; Nannini G and Meoni G drafted the manuscript; Tenori L, Luchinat C, and Amedei A revised the manuscript.

**Corresponding author: Amedeo Amedei, BSc, Reader (Associate Professor),** Department of Clinical and Experimental Medicine, University of Florence, Largo Brambilla 3, Florence 50134, Italy. aamedei@unifi.it

**Received:** March 9, 2021

**Revised:** May 17, 2021

**Accepted:** August 25, 2021

**Published online:** October 14, 2021

**Abstract**

BACKGROUND

Colorectal cancer (CRC), the third most common cause of death in both males and females worldwide, shows a positive response to therapy and usually a better prognosis when detected at an early stage. However, the survival rate declines when the diagnosis is late and the tumor spreads to other organs. Currently, the measures widely used in the clinic are fecal occult blood test and evaluation of serum tumor markers, but the lack of sensitivity and specificity of these markers restricts their use for CRC diagnosis. Due to its high sensitivity and precision, colonoscopy is currently the gold-standard screening technique for CRC, but it is a costly and invasive procedure. Therefore, the implementation of custom-made methodologies including those with minimal invasiveness, protection, and reproducibility is highly desirable. With regard to other screening methods, the screening of fecal samples has several benefits, and metabolomics is a successful method to classify the metabolite shift in living systems as a reaction to pathophysiological influences, genetic modifications, and environmental factors.

AIM

To characterize the variation groups and potentially recognize some diagnostic markers, we compared with healthy controls (HCs) the fecal nuclear magnetic resonance (NMR) metabolomic profiles of patients with CRC or adenomatous polyposis (AP).

METHODS

Proton nuclear magnetic resonance spectroscopy was used in combination with multivariate and univariate statistical approaches, to define the fecal metabolic profiles of 32 CRC patients, 16 AP patients, and 38 HCs well matched in age, sex, and body mass index.

RESULTS

NMR metabolomic analyses revealed that fecal sample profiles differed among CRC patients, AP patients, and HCs, and some discriminatory metabolites including acetate, butyrate, propionate, 3-hydroxyphenylacetic acid, valine, tyrosine and leucine were identified.

CONCLUSION

In conclusion, we are confident that our data can be a forerunner for future studies on CRC management, especially the diagnosis and evaluation of the effectiveness of treatments.

**Key Words:** Colorectal cancer; Adenomatous polyps; Nuclear magnetic resonance metabolomics; Fecal samples; Fecal metabolomics

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Nannini G, Meoni G, Tenori L, Ringressi MN, Taddei A, Niccolai E, Baldi S, Russo E, Luchinat C, Amedei A. Fecal metabolomic profiles: A comparative study of patients with colorectal cancer *vs* adenomatous polyps. *World J Gastroenterol* 2021; 27(38): 6430-6441

**URL:** https://www.wjgnet.com/1007-9327/full/v27/i38/6430.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v27.i38.6430

**Core Tip:** Colorectal cancer (CRC) isthe third leading cause of cancer-related death worldwide. Fecal occult blood and serum tumor markers are indicators currently used in the clinic, but their lack of sensitivity and precision limit their use for CRC diagnosis. Colonoscopy is the gold-standard screening technique for CRC, but it is costly and invasive. Using readily accessible biological samples such as stool specimens, in conjunction with high-throughput molecular profiling techniques, could significantly contribute to diagnosing and understanding the patient’s relationship with CRC. We compared with healthy subjects the fecal nuclear magnetic resonance metabolomic profiles of patients with CRC or adenomatous polyposis.

**INTRODUCTION**

Colorectal cancer (CRC) is globally the third most common cause of cancer-related death in both men and women[1]. Many CRC cases are attributable to changeable (and therefore potentially preventable)[2] risk factors including diet, smoking, high alcohol consumption, physical inactivity, and being overweight. If diagnosed at an early stage, CRC shows a good response to therapy and usually a better prognosis, while survival decreases when the diagnosis is late, and the tumor spreads to other organs[3]. In addition, it is well documented that about 95% of CRCs are adenocarcinomas and begin as colonic adenomatous polyps (AP)[4] or adenomas. A series of molecular alterations and mutations induce CRC development. Tumors can be prevented with polyps excision and adequate treatment[5]. The fecal occult blood test and evaluation of serum tumor markers are commonly used in the clinic[6]; however, the lack of sensitivity and specificity of these markers limits their application in CRC diagnosis[6-8]. Currently, colonoscopy represents the gold-standard screening procedure for CRC due to its high sensitivity and specificity, but it is an expensive and especially invasive procedure[9,10]. Therefore, it is highly desirable to introduce custom-made methodologies combining minimal invasiveness, safety, and reproducibility. The screening of fecal samples has many advantages with respect to other screening techniques. In fact, stool screening is certainly non-invasive and primarily reflects the colorectal status. Moreover, the use of easily accessible and non-invasive biological samples, such as stool specimens, combined with high-throughput molecular profiling techniques, can significantly contribute to the diagnosis of CRC and to the understanding of its interaction with the patient.

Metabolomics is an omics science that is an efficient approach to characterizing the change of metabolites in living systems as a response to pathophysiological stimuli, genetic modifications, and environmental factors. Metabolites are low molecular weight organic molecules that take part (as substrates or products) in the biochemical processes essential for sustaining life. Thus, the comprehensive evaluation of metabolites and their changes are fundamental to observe and measure the response of the organism to diverse conditions.

Nuclear magnetic resonance (NMR) spectroscopy is one of the most useful high-throughput techniques to obtain metabolomics information from biological samples[11,12]. NMR-based metabolomics has been successfully applied for disease classification[13-18] and prognosis. Starting from these premises, we compared the fecal NMR metabolomic profiles of patients with CRC or AP with those of healthy controls (HCs) to characterize the differences among the groups and possibly identify diagnostic markers.

**MATERIALS AND METHODS**

***Patients and biological samples***

A total of 86 patients including 32 CRC patients, 16 AP patients, and 38 HCs were enrolled for different studies between January 2016 and February 2019 at the Careggi Hospital and University of Florence, Italy. The Ethics Committee Area Vasta Toscana Centro (Italy) approved the studies. All fecal samples were taken at diagnosis, before starting any treatment (*e.g.,* surgical resection, chemotherapy, probiotic intake). Moreover, patients with evidence of serious illness, immunodeficit, autoimmune or infectious diseases were excluded. CRC patients, AP patients, and HCs were well matched in age, sex and body mass index. Table 1 summarizes the clinical characteristics of the enrolled patients.

Stool samples were collected in pre-labeled collection cups. Fecal water was extracted to ratios of 1:2 (g/mL, weight of unthawed feces-to-buffer) in 0.75 M phosphate-buffered saline (PBS, pH 7.4)[19]. The buffered samples where homogenized by whirl mixing for 30 s and sonicated for 15 min. Then each sample was centrifuged at 10000 g for 10 min at 4 °C, and 700 μL supernatant was transferred to 1.5 mL Eppendorf tubes and centrifuged again at 14000 rpm for 5 min at 4 °C. The clear supernatant was used for NMR analyses.

***NMR sample preparation and analyses***

A total of 70 μL buffer solution (1.5 M KH2PO4/d2O, pH 7.4; 2 mmol/L NaN3; 0.1% TMSP) was added to 630 μL of each fresh fecal water sample, and a total of 600 μL of this mixture was transferred to a 5 mm NMR tube.

One-dimensional proton NMR (1H-NMR) spectra for all samples were acquired using the Bruker 600 MHz spectrometer (Bruker BioSpin srl; Rheinstetten, Germany) operating at 600.13 MHz proton Larmor frequency and equipped with a 5 mm PATXI 1H-13C-15N and 2H-decoupling probe including a *z* axis gradient coil, an automatic tuning-matching, and an automatic and refrigerated sample changer (SampleJet, Bruker BioSpin srl; Rheinstetten).

The BTO 2000 thermocouple served for temperature stabilization at the level of approximately 0.1 K at the sample. Before measurement, samples were kept for at least 3 min inside the NMR probe head for temperature equilibration.

Two one-dimensional 1H-NMR spectra, namely one-dimensional (1D) NOESY and Carr-Purcell-Meiboom-Gill (CPMG), were acquired at 310 K with different pulse sequences: a standard nuclear Overhauser effect spectroscopy pulse sequence 1D NOESY PRESAT (noesygppr1d.comp; Bruker BioSpin) pulse sequence, using 64 scans, 98304 data points, a spectral width of 18028 Hz, an acquisition time of 2.7 s, a relaxation delay of 4 s, and a mixing time of 0.1 s; and a standard spin echo CPMG[20] (cpmgpr1d.comp; Bruker BioSpin) pulse sequence applied to a standard 1D sequence, with 64 scans, 73728 data points, a spectral width of 12019 Hz, and a relaxation delay of 4 s.

***Spectral processing and statistical analysis***

Free induction decays were multiplied by an exponential function equivalent to 0.3 Hz line-broadening factor before applying Fourier transform. Transformed spectra were automatically corrected for phase and baseline distortions and fecal spectra calibrated to TMSP singlet at 0 ppm using the TopSpin version 4.1.0 (Bruker BioSpin GmbH).

NMR spectra were segmented into bins of 0.02 ppm in the spectral range between 0.2 and 10.00 ppm. Regions containing residual water signal (between 4.6 and 4.9 ppm) were removed from the binning. The spectral intensity within each bin was integrated using Assure NMR 2.2, and the corresponding area was calculated to obtain the variable used as input for the statistical methods.

Before analysis of the generated data matrix, probabilistic quotient normalization[21] normalization and mean centering of the variables were performed.

Statistical analyses of the data were performed using R[22]. On processed NMR spectra, multivariate data analyses were performed. Principal component analysis (PCA) was used as unsupervised technique for exploratory analyses to check the homogeneity of the acquired spectra and to visualize the presence of outliers. As a supervised technique, orthogonal projections to latent structures-discriminant analysis (OPLS-DA) was applied. The OPLS-DA method is a multivariate projection approach that is commonly used to model spectroscopic data. Compared to PCA or partial least squares projection to latent structures (PLS), OPLS is able to distinguish between “response-related” and “response-orthogonal” fluctuations in data, delivering benefits in terms of model interpretation[23]. All of the accuracies reported and the confusion matrix for different classifications were assessed by means of 100 cycles of the Monte Carlo cross-validation scheme (MCCV, R script developed in-house). In this case, 90% of the data were randomly chosen at each iteration as a training set to build the model. Then the remaining 10% was tested, and the sensitivity, specificity, and accuracy of the classification were assessed. Metabolite identification was performed manually based on previous literature[19,24], the human metabolome database public database, and a library of pure organic compounds (BBIOREFCODE; Bruker BioSpin). The relative metabolite concentrations (expressed in arbitrary units) were calculated integrating and calculating the peaks area[25].

To determine the discriminating molecules among all classes under study, the Wilcoxon test was chosen to infer differences between two groups of subjects[26]. False discovery rate (FDR) correction was applied using the Benjamini & Hochberg method, and adjusted *P* < 0.05 was considered statistically significant[27]. The effect size, using the Cliff’s delta (Cd) formulation[28], was also calculated to aid in the identification of the meaningful signals giving an estimation of the magnitude of the separation between the different groups. The magnitude was assessed using the thresholds provided in Romano and Coll[29], *i.e.* |Cd| < 0.147 “negligible,” |Cd| < 0.33 “small,” |Cd| < 0.474 “medium,”and otherwise “large.”

Changes in metabolite levels were calculated as the log2 (fold change) ratio of the normalized median intensities of the corresponding signals in the spectra of the two groups. MetaboAnalyst 4.0 free online software was used for pathway analysis[30].

**RESULTS**

***Metabolic fingerprint of CRC and AP patients***

The NMR spectra of 86 fecal extract samples (32 CRC, 16 AP, and 38 HC) were acquired. Because of the suboptimal shimming quality of 7 spectra, only 79 spectra (1D NOESY: 26 CRC, 15 AP and 38 HCs; CPMG: 27 CRC, 14 AP, and 38 HCs) were used in subsequent analyses.

PCA was initially carried out to generate an overview of the variation among the different groups of patients (CRC, AP, and HCs) using bucketed spectra of fecal extracts. Some trends could be detected in the score plots of the first two principal components as shown in Supplementary Figure 1. Indeed, both score plots reveal that CRC and AP patient groups tend to spread in the plots more than HCs that are more grouped. However, no net clustering seems to appear in the metabolomic profiles of the groups of patients neither with respect to HCs using this unsupervised approach.

Comparative analyses among the groups have been performed to test the capability of 1H-NMR fecal water spectra to classify the samples of the patients according to the diagnosis. Several models have been built using a MC cross-validated supervised OPLS-DA approach. First, all three groups (CRC, AP, and HCs) were used in the same model to test the accuracy of the approach in the prediction of the healthy or the pathological state using a single bucketed NMR fecal spectrum (Supplementary Figure 2). As is shown in the score plots of Supplementary Figure 2, the AP samples occupied the middle metabolomic space between HCs and CRC. Indeed, the resulting true AP-positive percentages of the OPLS-DA NOESY and CPMG models were 37.7% and 18%, respectively (Supplementary Figure 2), and most of the AP patients were misclassified within the metabolomic space of HCs or CRC.

Prognostic data about patients are not available therefore was impossible to assess whether the AP patients predicted within the metabolomic space of CRC were more predisposed to developing cancer.

The capability to correctly classify HCs provides another important challenge for clinical screening. Indeed, other OPLS-DA models have been attempted to distinguish the fecal water spectra of HCs compared to AP + CRC patients yielding an overall predictive accuracy of 85.3% using 1D NOESY binned spectra (Table 2, Supplementary Figure 3A).

Furthermore, separated models were established comparing separately the 1HNMR binned spectra of HCs *vs* CRC, HCs *vs* AP, and CRC *vs* AP patients (Table 2, Supplementary Figure 3B-D). As reported in Table 2, all models built on 1D NOESY bucketed spectra are better performing than those built on CPMG spectra.Supplementary Figure 3 shows the score plots related to the higher predictive accuracy among the models listed in Table 2. The reported models suggest the existence of a metabolomic fingerprint in fecal extracts of CRC and AP compared with HCs, confirming what was previously suggested by PCA and the literature available[24,31-33].

In most biofluids, low mass metabolites coexist with high mass biomolecules such as lipids, proteins, and lipoproteins. Here, two NMR pulse sequences were used to selectively observe the different components: 1D NOESY pulse sequence yields a spectrum in which both signals of metabolites and high molecular weight molecules (*e.g.*, lipids, lipoproteins, and albumin) are visible; the CPMG pulse sequence enables the selective observation of small molecule components in solutions containing macromolecules (*via* T2 filtering). Representative one-dimensional 1H-NMR spectra of fecal extracts obtained with the mentioned pulse sequences are shown in Supplementary Figure 4. Indeed, NOESY experiments, which are sensitive to both low and high molecular weight compounds, resulted more accurate classifiers of all of the cases considered in this study and are described in Table 2 (HCs *vs* AP and CRC: sensitivity 84.9%, specificity 85.7%, predictive accuracy 85.3%; HCs *vs* CRC: sensitivity 85.0%, specificity 88.6%, accuracy 86.8%; HCs *vs* AP: sensitivity 71.7.8%, specificity 83.8%, predictive accuracy 77.8%: AP *vs* CRC: sensitivity 87.4%, specificity 71.6%, predictive accuracy 79.5%).

***Metabolic profiles of CRC and AP patients***

With the aim of identifying metabolite-level variations characteristic for each group, univariate analyses were applied to the identified fecal metabolites. Marked changes were observed in the metabolic profiles of fecal samples between CRC patients and HCs. Indeed, the first were characterized by a significantly lower content of 3-hydroxyphenylacetate, methanol, galactose, acetate, xylose and isobutyrate and a higher content of glycerol and phenylalanine (Figure 1A). Compared to HCs, AP patients had significantly lower amounts of 3-hydroxyphelylacetate, butyrate, acetate, propionate, isobutyrate and lactate+threonine (considered together because of the overlapping doublets at 1.33 ppm) as reported in Figure 1C. In CRC fecal extract profiles, when compared to AP patients, only leucine, tyrosine, and valine remained statistically significant and were present in higher amounts (Figure 1B). The complete list of fecal extract metabolites identified is reported in Supplementary Table 1. The most relevant pathways identified are reported inTable 3 and Supplementary Figure 5.

The top six identified metabolomic pathways in CRC (*P* < 0.05) were aminoacyl-tRNA biosynthesis, phenylalanine, tyrosine and tryptophan biosynthesis, valine, leucine and isoleucine biosynthesis, phenylalanine and galactose metabolism and valine, leucine and isoleucine degradation. Among them, valine, leucine and isoleucine biosynthesis, aminoacyl-tRNA biosynthesis, valine, leucine and isoleucine degradation and phenylalanine, tyrosine and tryptophan biosynthesis pathways were also altered in AP patients (Table 3).

**DISCUSSION**

In this study, we evaluated the fecal metabolomic profiles of CRC and AP patients with respect to HCs using NMR spectroscopy. The metabolome is a quantitative collection of low molecular weight compounds generated by metabolism[34]. Metabolomics is an emerging field of research downstream from genomics, proteomics, and transcriptomics. The metabolic screening of stool samples, which reflects the colorectal status, might contribute to the development of non-invasive screening tests[35,36]. The power of metabolomics consists in the capacity to detect and characterize tumors because cellular metabolism alterations represent a key hallmark of cancer[37]. To date, studies evaluating fecal metabolic changes associated with CRC are still lacking. Notably, no study has described fecal metabolomic changes associated with adenoma. Despite the high variability in fecal water profiles, reliable metabolic differences between patients and HCs were observed by preliminary analyses of the spectra. First, the PCA of the 1H-NMR spectral data was carried out to identify some trends and outliers, showing some separation among cancer, adenoma, and HC groups. However, this unsupervised approach does not seem to clearly characterize the groups. These results were not surprising in light of the inter-individual variability introduced with diet, lifestyle, sex *etc.*

To optimize the separation among groups, we used OPLS-DA MCCV models, which were effective in discriminating the fecal metabolomic fingerprints of CRC patients and HCs (overall predictive accuracy of 93.7%). From the above analyses we can conclude that both low and high molecular weight molecules, visible using the 1D NOESY pulse sequence, are important to characterize at metabolic level the two pathological profiles. Moreover, the capability to accurately predict HCs when compared to patients with colonic AP or adenomas and CRC patients (showed predictive accuracy of 85.3%) using 1H-NMR fecal water spectra, could be tested on a larger number of subjects to develop fast screening following a positive fecal occult blood test in order to spare colonoscopy in some patients who have bleeding due to other reasons[38,39].

In detail, the short-chain fatty acids (SCFAs) were found to be significantly decreased in CRC and AP patients, and in particular, lower levels of acetate were observed with respect to the HCs. SCFAs are microbial-derived metabolites, produced through gut bacteria fermentation of complex carbohydrates. SCFAs can be absorbed by the colonic epithelium, suppling energy and playing a crucial role in the regulation of fatty acids, glucose, and cholesterol metabolism[40-43]. A decrease in SCFA abundance is strictly linked to an unhealthy gut microbiota status, and alterations in the fecal SCFA profile may be the result of gut microbiota dysbiosis, inflammatory changes, or both[44]. Our data confirmed what has been previously reported by other studies. In particular, the analyses by Lin *et al*[45] demonstrated a high diagnostic performance of fecal acetate in CRC patients with respect to HCs.

In contrast with previous data, we did not find decreased levels of butyric acid in CRC patients with respect to HCs; however, we observed significantly decreased levels in AP. Butyric acid has an important homeostatic role in the human colon, and *in vitro* and *in vivo* studies have demonstrated its ability in preventing CRC[46-48]. However, other studies have showed contrasting results, suggesting a pro-cancer role of butyric acid, and low levels of butyrate usually seem to be linked with CRC development[31,35]. This double-edged role is named “butyrate paradox”[49,50]. Our results could be very interesting in this respect, suggesting that low levels of butyric acid in adenoma could lead to CRC development, while “normal” levels of butyrate in CRC could support cancer progression and promote the differentiation of regulatory T cells, which show a pro- tumorigenic role[51], especially in advanced CRC.

In addition, we found significantly low levels of 3-hydroxyphenylacetic (3-HPAA) acid in both CRC and AP patients. 3-HPAA acid is a weak acid and one of the most abundant products of polyphenol degradation in the large intestine[52,53]. Food polyphenols are broken down into other phenolic compounds by colonic bacteria action. In this way, poorly absorbable large-size polyphenols are converted to small-sized bioavailable metabolites, including 3-HPAA, which could be more biologically active[54,53]. Polyphenolic colon metabolites could be important endogenous antioxidants able to scavenge excess of free radicals, suppressing their effects on protein, lipid, and DNA damage[55]. A recent study demonstrated that polyphenol metabolites produced by colonic microbiota reduce some enzymatic activities involved in human tumorigenesis[56]. 3-HPAA can act as a CRC preventive agent by inhibition of cyclooxygenase-2 (COX-2)[57], a mediator of inflammation that is significantly overexpressed in a variety of human malignancies. Moreover, some studies have reported that COX-2 inhibitors not only prevent tumor formation but also decrease the number of already established polyps in patients with familial AP[58]. Accordingly, our results suggest that low levels of 3-HPAA are insufficient to inhibit COX-2, and consequently COX-2 expression can promote the development, tumor growth, immune suppression, angiogenesis, and metastasis of cancer cells.

Furthermore, higher amounts of amino acids such as leucine, tyrosine and valine, were present in the stool of CRC patients (compared to AP), probably resulting from malabsorption due to large epithelial inflammation and damage associated with CRC[59]. Previous metabolomic studies on fecal water have suggested that amino acid concentrations mirror the malabsorption of nutrients caused by the malfunction of epithelium barrier protection[60]. In agreement with previous studies, we documented higher levels of amino acids in the fecal water of CRC patients[31,35,61]. Alterations of amino acid levels can be associated with altered cancer cell activities, including the synthesis of proteins or catabolism to provide energy and/or other metabolite substrates.

**CONCLUSION**

In summary, our NMR metabolomics investigation revealed for the first time that fecal sample profiles can discriminate among CRC AP, AP patients and HCs, and some discriminatory metabolites were identified including acetate, butyrate, propionate, 3-HPAA acid, valine, tyrosine, and leucine. These altered metabolites suggest that changes in CRC and adenoma are associated with different pathway perturbations including valine, leucine and isoleucine biosynthesis, aminoacyl-tRNA biosynthesis, valine, leucine and isoleucine degradation phenylalanine, tyrosine and tryptophan biosynthesis, phenylalanine metabolism and galactose metabolism. In conclusion, we are confident that our data can be a forerunner for future studies on CRC management, especially the diagnostics and evaluation of the effectiveness of the treatments.

**ARTICLE HIGHLIGHTS**

***Research background***

Colorectal cancer (CRC) is globally the third most common cause of death. If diagnosed at an early stage, CRC shows a good response to therapy and usually a better prognosis. Unfortunately, despite its invasiveness, colonoscopy represents the gold-standard screening procedure for CRC.

***Research motivation***

Considering that colonoscopy is an expensive and invasive procedure, it seems to be essential to introduce custom-made methodologies combining minimal invasiveness, safety, and reproducibility. Fecal sample screening has many advantages with respect to other screening techniques.

***Research objectives***

The main objective of our study was to compare with HCs (HCs) the fecal nuclear magnetic resonance (NMR) metabolomic profiles of patients with CRC or adenomatous polyposis (AP) to characterize the variations among the groups and potentially identify some diagnostic markers.

***Research methods***

In order to define the fecal metabolic profile of 32 CRC, 16 AP patients and 38 HCs we used proton nuclear magnetic resonance spectroscopy in combination with multivariate and univariate statistical approaches.

***Research results***

The NMR spectra of 86 fecal extract samples have been acquired.With the aim of identifying metabolite level variations characteristic for each group, univariate analyses were applied to the identified fecal metabolites. The most marked changes were observed in the metabolic profiles of fecal samples of CRC patient *vs* HCs. AP patients, compared to HCs show significant lower amount of 3-hydroxyphelylacetate, butyrate, acetate, propionate, isobutyrate and lactate+threonine. In CRC fecal extract profiles, when compared to AP patients, only leucine, tyrosine, and valine remained statistically significant and present in higher amounts.

***Research conclusions***

The metabolic screening of stool samples might contribute to the development of non-invasive screening tests. To date, studies evaluating fecal metabolic changes associated with CRC are still lacking. Furthermore, no study has described fecal metabolomic changes associated with adenoma. The short-chain fatty acids were found to be significantly decreased in CRC and AP patients, and in particular, lower levels of acetate were observed with respect to HCs. In contrast with previous data, we did not find decreased levels of butyric acid in CRC patients compared to HCs; however, we observed significantly decreased levels in AP patients. We showed significantly low levels of 3-hydroxyphenylacetic (3-HPAA) acid in both CRC and AP patients. Finally, higher amounts of amino acids such as leucine, tyrosine, and valine were present in the stool of CRC patients (compared to AP), probably resulting from malabsorption due to large epithelial inflammation and damage.

***Research perspectives***

For the first time, we showed that fecal sample profiles can discriminate among CRC patients, AP patients and HCs, and some discriminatory metabolites were identified including acetate, butyrate, propionate, 3-HPAA acid, valine, tyrosine, and leucine. We believe that our data will be a starting point for future studies on CRC management, especially the diagnostics and evaluation of the effective of the treatments.

**REFERENCES**

1 **Rawla P**, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. *Prz Gastroenterol* 2019; **14**: 89-103 [PMID: 31616522 DOI: 10.5114/pg.2018.81072]

2 **Islami F**, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, McCullough ML, Patel AV, Ma J, Soerjomataram I, Flanders WD, Brawley OW, Gapstur SM, Jemal A. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. *CA Cancer J Clin* 2018; **68**: 31-54 [PMID: 29160902 DOI: 10.3322/caac.21440]

3 **The Lancet**. Toward better control of colorectal cancer. *Lancet* 2014; **383**: 1437 [PMID: 24766949 DOI: 10.1016/S0140-6736(14)60699-1]

4 **Manne U**, Shanmugam C, Katkoori VR, Bumpers HL, Grizzle WE. Development and progression of colorectal neoplasia. *Cancer Biomark* 2010; **9**: 235-265 [PMID: 22112479 DOI: 10.3233/CBM-2011-0160]

5 **Yang L**, Wang S, Lee JJ, Lee S, Lee E, Shinbrot E, Wheeler DA, Kucherlapati R, Park PJ. An enhanced genetic model of colorectal cancer progression history. *Genome Biol* 2019; **20**: 168 [PMID: 31416464 DOI: 10.1186/s13059-019-1782-4]

6 **Nannini G**, Meoni G, Amedei A, Tenori L. Metabolomics profile in gastrointestinal cancers: Update and future perspectives. *World J Gastroenterol* 2020; **26**: 2514-2532 [PMID: 32523308 DOI: 10.3748/wjg.v26.i20.2514]

7 **Weitz J**, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. *Lancet* 2005; **365**: 153-165 [PMID: 15639298 DOI: 10.1016/S0140-6736(05)17706-X]

8 **Huerta S**. Recent advances in the molecular diagnosis and prognosis of colorectal cancer. *Expert Rev Mol Diagn* 2008; **8**: 277-288 [PMID: 18598107 DOI: 10.1586/14737159.8.3.277]

9 **Issa IA**, Noureddine M. Colorectal cancer screening: An updated review of the available options. *World J Gastroenterol* 2017; **23**: 5086-5096 [PMID: 28811705 DOI: 10.3748/wjg.v23.i28.5086]

10 **Young PE**, Womeldorph CM. Colonoscopy for colorectal cancer screening. *J Cancer* 2013; **4**: 217-226 [PMID: 23459594 DOI: 10.7150/jca.5829]

11 **Zhang A,** Sun H, Wang P, Han Y, Wang X. Recent and potential developments of biofluid analyses in metabolomics. *J Proteomics 2012*; **75**:1079-1088 [PMID: 22079244 DOI: 10.1016/j.jprot.2011.10.027]

12 **Vignoli A**, Ghini V, Meoni G, Licari C, Takis PG, Tenori L, Turano P, Luchinat C. High-Throughput Metabolomics by 1D NMR. *Angew Chem Int Ed Engl* 2019; **58**: 968-994 [PMID: 29999221 DOI: 10.1002/anie.201804736]

13 **Singh MP**, Saxena M, Saimbi CS, Siddiqui MH, Roy R. Post-periodontal surgery propounds early repair salivary biomarkers by 1 H NMR based metabolomics. *Metabolomics* 2019; **15** :141. [PMID: 31612356 DOI: 10.1007/s11306-019-1593-3]

14 **Meoni G**, Lorini S, Monti M, Madia F, Corti G, Luchinat C, Zignego AL, Tenori L, Gragnani L. The metabolic fingerprints of HCV and HBV infections studied by Nuclear Magnetic Resonance Spectroscopy. *Sci Rep* 2019; **9**: 4128 [PMID: 30858406 DOI: 10.1038/s41598-019-40028-4]

15 **Obi AT**, Stringer KA, Diaz JA, Finkel MA, Farris DM, Yeomans L, Wakefield T, Myers DD Jr. 1D-¹H-nuclear magnetic resonance metabolomics reveals age-related changes in metabolites associated with experimental venous thrombosis. *J Vasc Surg Venous Lymphat Disord* 2016; **4**: 221-230 [PMID: 26993871 DOI: 10.1016/j.jvsv.2015.09.010]

16 **Debik J**, Euceda LR, Lundgren S, Gythfeldt HVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF, Giskeødegård GF. Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients. *J Proteome Res* 2019; **18**: 3649-3660 [PMID: 31483662 DOI: 10.1021/acs.jproteome.9b00316]

17 **Hao J**, Yang T, Zhou Y, Gao GY, Xing F, Peng Y, Tao YY, Liu CH. Serum Metabolomics Analysis Reveals a Distinct Metabolic Profile of Patients with Primary Biliary Cholangitis. *Sci Rep.* 2017; **7**:784. [PMID: 28400566DOI: 10.1038/s41598-017-00944-9]

18 **Fulghesu AM**, Piras C, Dessì A, Succu C, Atzori L, Pintus R, Gentile C, Angioni S, Fanos V. Urinary Metabolites Reveal Hyperinsulinemia and Insulin Resistance in Polycystic Ovarian Syndrome (PCOS). *Metabolites* 2021; **11** [PMID: 34357331 DOI: 10.3390/METABO11070437]

19 **Lamichhane S**, Yde CC, Schmedes MS, Jensen HM, Meier S, Bertram HC. Strategy for Nuclear-Magnetic-Resonance-Based Metabolomics of Human Feces. *Anal Chem* 2015; **87**: 5930-5937 [PMID: 25985090 DOI: 10.1021/acs.analchem.5b00977]

20 **Meiboom S,** Gill D, Modified Spin-Echo Method for Measuring Nuclear Relaxation Times. *Rev Sci Instru* 2004; **29**: 688 [DOI: 10.1063/1.1716296]

21 **Dieterle F**, Ross A, Schlotterbeck G, Senn H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. *Anal Chem* 2006; **78**: 4281-4290 [PMID: 16808434 DOI: 10.1021/ac051632c]

22 **Ihaka R,** Gentleman R, R: A Language for Data Analysis and Graphics. *J Comput* *Graph* *Stat* 1996; **5**: 299 [DOI: 10.2307/1390807]

23 **Westerhuis JA**, van Velzen EJ, Hoefsloot HC, Smilde AK. Multivariate paired data analysis: multilevel PLSDA *vs* OPLSDA. *Metabolomics* 2010; **6**: 119-128 [PMID: 20339442 DOI: 10.1007/s11306-009-0185-z]

24 **Bertini I**, Cacciatore S, Jensen BV, Schou JV, Johansen JS, Kruhøffer M, Luchinat C, Nielsen DL, Turano P. Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. *Cancer Res* 2012; **72**: 356-364 [PMID: 22080567 DOI: 10.1158/0008-5472.CAN-11-1543]

25 **Onitilo AA**, Kio E, Doi SA. Tumor-related hyponatremia. *Clin Med Res* 2007; **5**: 228-237 [PMID: 18086907 DOI: 10.3121/cmr.2007.762]

26 **Wilcoxon F.** Individual Comparisons by Ranking Methods. *Biom Bull* 1945; **1**: 80 [DOI: 10.2307/3001968]

27 **Benjamini Y**, Hochberg Y. On the Adaptive Control of the False Discovery Rate in Multiple Testing With Independent Statistics. *J Educ Behav Stat* 2000; **25**: 60-83 [DOI: 10.3102/10769986025001060]

28 **Cliff N**. Ordinal Methods for Behavioral Data Analysis. *Psychology* 1996; In press

29 **Romano JS,** Kromrey J, Coraggio J. Appropriate statistics for ordinal level data: Should we really be using t-test and Cohen’sd for evaluating group differences on the NSSE and other surveys? Annual Meeting of the Florida Association of Institutional Research. 2006: 1-3

30 **Chong J**, Yamamoto M, Xia J. MetaboAnalystR 2.0: From Raw Spectra to Biological Insights. *Metabolites* 2019; **9** [PMID: 30909447 DOI: 10.3390/metabo9030057]

31 **Lin Y**, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R. NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. *Oncotarget* 2016; **7**: 29454-29464 [PMID: 27107423 DOI: 10.18632/oncotarget.8762]

32 **Farshidfar F**, Weljie AM, Kopciuk KA, Hilsden R, McGregor SE, Buie WD, MacLean A, Vogel HJ, Bathe OF. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics. *Br J Cancer* 2016; **115**: 848-857 [PMID: 27560555 DOI: 10.1038/bjc.2016.243]

33 **Gu J**, Xiao Y, Shu D, Liang X, Hu X, Xie Y, Lin D, Li H. Metabolomics Analysis in Serum from Patients with Colorectal Polyp and Colorectal Cancer by 1H-NMR Spectrometry. *Dis Markers* 2019; **2019**: 3491852 [PMID: 31089393 DOI: 10.1155/2019/3491852]

34 **Claudino WM**, Quattrone A, Biganzoli L, Pestrin M, Bertini I, Di Leo A. Metabolomics: available results, current research projects in breast cancer, and future applications. *J Clin Oncol* 2007; **25**: 2840-2846 [PMID: 17502626 DOI: 10.1200/JCO.2006.09.7550]

35 **Monleón D**, Morales JM, Barrasa A, López JA, Vázquez C, Celda B. Metabolite profiling of fecal water extracts from human colorectal cancer. *NMR Biomed* 2009; **22**: 342-348 [PMID: 19006102 DOI: 10.1002/nbm.1345]

36 **Wang C**, Ke C, Wang X, Chi C, Guo L, Luo S, Guo Z, Xu G, Zhang F, Li E. Noninvasive detection of colorectal cancer by analysis of exhaled breath. *Anal Bioanal Chem* 2014; **406**: 4757-4763 [PMID: 24820062 DOI: 10.1007/s00216-014-7865-x]

37 **García-Cañaveras JC**, Lahoz A. Tumor Microenvironment-Derived Metabolites: A Guide to Find New Metabolic Therapeutic Targets and Biomarkers. *Cancers (Basel)* 2021; **13** [PMID: 34203535 DOI: 10.3390/CANCERS13133230]

38 **Bardhan PK**, Beltinger J, Beltinger RW, Hossain A, Mahalanabis D, Gyr K. Screening of patients with acute infectious diarrhoea: evaluation of clinical features, faecal microscopy, and faecal occult blood testing. *Scand J Gastroenterol* 2000; **35**: 54-60 [PMID: 10672835 DOI: 10.1080/003655200750024533]

39 **Harewood GC**, Ahlquist DA. Fecal occult blood testing for iron deficiency: a reappraisal. *Dig Dis* 2000; **18**: 75-82 [PMID: 11060470 DOI: 10.1159/000016968]

40 **Moos WH**, Faller DV, Harpp DH, Kanara I, Pernokas J, Powers WR, Steliou K. Microbiota and Neurological Disorders: A Gut Feeling. *BioResearch* 2016; **5**: 137-145 [DOI: 10.1089/biores.2016.0010]

41 **Davis CD**, Milner JA. Gastrointestinal microflora, food components and colon cancer prevention. *J Nutr Biochem* 2009; **20**: 743-752 [PMID: 19716282 DOI: 10.1016/j.jnutbio.2009.06.001]

42 **Kasubuchi M**, Hasegawa S, Hiramatsu T, Ichimura A, Kimura I. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. *Nutrients* 2015; **7**: 2839-2849 [PMID: 25875123 DOI: 10.3390/nu7042839]

43 **Natarajan N**, Pluznick JL. From microbe to man: the role of microbial short chain fatty acid metabolites in host cell biology. *Am J Physiol Cell Physiol* 2014; **307**: C979-C985 [PMID: 25273884 DOI: 10.1152/ajpcell.00228.2014]

44 **Feng W**, Ao H, Peng C. Gut Microbiota, Short-Chain Fatty Acids, and Herbal Medicines. *Front Pharmacol* 2018; **9**: 1354 [PMID: 30532706 DOI: 10.3389/fphar.2018.01354]

45 **Lin Y**, Ma C, Bezabeh T, Wang Z, Liang J, Huang Y, Zhao J, Liu X, Ye W, Tang W, Ouyang T, Wu R. 1 H NMR-based metabolomics reveal overlapping discriminatory metabolites and metabolic pathway disturbances between colorectal tumor tissues and fecal samples. *Int J Cancer* 2019; **145**: 1679-1689 [PMID: 30720869 DOI: 10.1002/ijc.32190]

46 **Zhang M**, Zhou Q, Dorfman RG, Huang X, Fan T, Zhang H, Zhang J, Yu C. Butyrate inhibits interleukin-17 and generates Tregs to ameliorate colorectal colitis in rats. *BMC Gastroenterol* 2016; **16**: 84 [PMID: 27473867 DOI: 10.1186/s12876-016-0500-x]

47 **Zeng H**, Taussig DP, Cheng WH, Johnson LK, Hakkak R. Butyrate Inhibits Cancerous HCT116 Colon Cell Proliferation but to a Lesser Extent in Noncancerous NCM460 Colon Cells. *Nutrients* 2017; **9** [PMID: 28045428 DOI: 10.3390/nu9010025]

48 **Singh N**, Gurav A, Sivaprakasam S, Brady E, Padia R, Shi H, Thangaraju M, Prasad PD, Manicassamy S, Munn DH, Lee JR, Offermanns S, Ganapathy V. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. *Immunity* 2014; **40**: 128-139 [PMID: 24412617 DOI: 10.1016/j.immuni.2013.12.007]

49 **Belcheva A**, Irrazabal T, Robertson SJ, Streutker C, Maughan H, Rubino S, Moriyama EH, Copeland JK, Surendra A, Kumar S, Green B, Geddes K, Pezo RC, Navarre WW, Milosevic M, Wilson BC, Girardin SE, Wolever TMS, Edelmann W, Guttman DS, Philpott DJ, Martin A. Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells. *Cell* 2014; **158**: 288-299 [PMID: 25036629 DOI: 10.1016/j.cell.2014.04.051]

50 **Niccolai E**, Baldi S, Ricci F, Russo E, Nannini G, Menicatti M, Poli G, Taddei A, Bartolucci G, Calabrò AS, Stingo FC, Amedei A. Evaluation and comparison of short chain fatty acids composition in gut diseases. *World J Gastroenterol* 2019; **25**: 5543-5558 [PMID: 31576099 DOI: 10.3748/wjg.v25.i36.5543]

51 **Niccolai E**, Ricci F, Russo E, Nannini G, Emmi G, Taddei A, Ringressi MN, Melli F, Miloeva M, Cianchi F, Bechi P, Prisco D, Amedei A. The Different Functional Distribution of "Not Effector" T Cells (Treg/Tnull) in Colorectal Cancer. *Front Immunol* 2017; **8**: 1900 [PMID: 29375559 DOI: 10.3389/fimmu.2017.01900]

52 **Halliwell B**, Rafter J, Jenner A. Health promotion by flavonoids, tocopherols, tocotrienols, and other phenols: direct or indirect effects? Antioxidant or not? *Am J Clin Nutr* 2005; **81**: 268S-276S [PMID: 15640490 DOI: 10.1093/ajcn/81.1.268S]

53 **Henning SM**, Wang P, Abgaryan N, Vicinanza R, de Oliveira DM, Zhang Y, Lee RP, Carpenter CL, Aronson WJ, Heber D. Phenolic acid concentrations in plasma and urine from men consuming green or black tea and potential chemopreventive properties for colon cancer. *Mol Nutr Food Res* 2013; **57**: 483-493 [PMID: 23319439 DOI: 10.1002/mnfr.201200646]

54 **Selma MV**, Espín JC, Tomás-Barberán FA. Interaction between phenolics and gut microbiota: role in human health. *J Agric Food Chem* 2009; **57**: 6485-6501 [PMID: 19580283 DOI: 10.1021/jf902107d]

55 **Amić A**, Marković Z, Marković JMD, Jeremić S, Lučić B, Amić D. Free radical scavenging and COX-2 inhibition by simple colon metabolites of polyphenols: A theoretical approach. *Comput Biol Chem* 2016; **65**: 45-53 [PMID: 27750207 DOI: 10.1016/j.compbiolchem.2016.09.013]

56 **Miene C**, Weise A, Glei M. Impact of polyphenol metabolites produced by colonic microbiota on expression of COX-2 and GSTT2 in human colon cells (LT97). *Nutr Cancer* 2011; **63**: 653-662 [PMID: 21598179 DOI: 10.1080/01635581.2011.552157]

57 **Karlsson PC**, Huss U, Jenner A, Halliwell B, Bohlin L, Rafter JJ. Human fecal water inhibits COX-2 in colonic HT-29 cells: role of phenolic compounds. *J Nutr* 2005; **135**: 2343-2349 [PMID: 16177193 DOI: 10.1093/jn/135.10.2343]

58 **Rostom A**, Dubé C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D; U.S. Preventive Services Task Force. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. *Ann Intern Med* 2007; **146**: 376-389 [PMID: 17339623 DOI: 10.7326/0003-4819-146-5-200703060-00010]

59 **Trinchieri G**. Cancer and inflammation: an old intuition with rapidly evolving new concepts. *Annu Rev Immunol* 2012; **30**: 677-706 [PMID: 22224761 DOI: 10.1146/annurev-immunol-020711-075008]

60 **Marchesi JR**, Holmes E, Khan F, Kochhar S, Scanlan P, Shanahan F, Wilson ID, Wang Y. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. *J Proteome Res* 2007; **6**: 546-551 [PMID: 17269711 DOI: 10.1021/pr060470d]

61 **Weir TL**, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. *PLoS One* 2013; **8**: e70803 [PMID: 23940645 DOI: 10.1371/journal.pone.0070803]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana, Sezione AREA VASTA CENTRO Institutional Review Board (CE: 11166\_spe and 13080\_oss).

**Conflict-of-interest statement:** All other authors have nothing to disclose.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** March 9, 2021

**First decision:** May 1, 2021

**Article in press:** August 25, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Wang KW **S-Editor:** Wu YXJ **L-Editor:** Filipodia **P-Editor:** Liu JH

**Figure Legends**



**Figure 1 Fecal water metabolite levels of colorectal cancer, polyps’ patients and healthy controls.** Boxplots of fold-change (FC) values for the significantly altered metabolites. Red bars represent metabolites levels that remain significant after the false discovery rate (FDR) correction (FDR *P* < 0.05), green bars are the metabolites that are no more significant after the FDR correction (*P* < 0.05). Cliff’s delta effect size is also reported for each metabolites in the comparisons (a: Small effect, b: Medium effect, c: Large effect). A:Comparison between healthy controls (HCs) and colorectal cancer (CRC) patients, negative log2(FC) values mean lower metabolite levels in CRC fecal samples, positive log2(FC) values report higher content in CRC compared to HCs; B: Negative log2(FC) represent higher metabolite levels in CRC patients compared to polyp patients; C: Comparison between HCs and polyp patient-negative log2(FC) values mean lower metabolite levels in polyp patients fecal water.

**Table 1 Clinical characteristics of colorectal cancer patients, adenomatous patients, and healthy controls**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Code** | **Gender ratio m/F** | **Median age, yr** | **Range of age, yr** | **Tumor staging T0/T1/T2/T3/T4 (*n* of patients)** | **Diet** | **Race** |
| CRC | 22 M-10 F; M/F = 2, 2 | 72 | 36-85 | 2/6/10/6/8 | Mediterranean | Caucasian |
| AP | 9M-7F; M/F = 1, 3 | 59 | 41-79 | - | Mediterranean | Caucasian |
| HS | 28M-10F; M/F = 2,8 | 47 | 27-68 | - | Mediterranean | Caucasian |

AP: Adenomatous patients; CRC: Colorectal cancer; HCs: Healthy controls.

**Table 2 Summary of orthogonal projections to latent structures-discriminant analysis models built fecal water spectra acquired using selective one-dimensional proton nuclear magnetic resonance pulse sequences, sensitivity (%), specificity (%) and predictive accuracy (%) assessed following 100 runs of Monte Carlo cross-validation are reported for each model**

|  |  |
| --- | --- |
|  | **1H NMR fecal extract spectra OPLS-DA cv models** |
| **Group (*n* of samples)** | **Pulse sequences** | **Sensitivity (%)** | **Specificity (%)** | **Predictive accuracy (%)** |
| HS (38) *vs* AP&CRC (41) | 1D noesy; CPMG | 84.9 | 85.7 | 85.3 |
| HS (38) *vs* AP&CRC (41) | 77.5 | 83.8 | 80.5 |
| HS (38) *vs* CRC (26) | 1D noesy; CPMG | 94.2 | 90.2 | 93.7 |
| HS (38) *vs* CRC (27) | 97.3 | 85.2 | 91.0 |
| HS (38) *vs* AP (15) | 1D noesy; CPMG | 90.8 | 76.6 | 87.0 |
| HS (38) *vs* AP (14) | 69.0 | 67.6 | 81.1 |
| AP (15) *vs* CRC (26) | 1D noesy; CPMG | 77.0 | 90.4 | 79.3 |
| AP (14) *vs* CRC (27) | 67.5 | 74.0 | 72.7 |

AP: Adenomatous patients; CPMG: Carr-Purcell-Meiboom-Gill; CRC: Colorectal cancer.

1HNMR: One-dimensional proton nuclear magnetic resonance; HCs: Healthy controls; OPLS-DA: Orthogonal projections to latent structures-discriminant analysis.

**Table 3 Identified pathways from fecal water metabolites**

|  |
| --- |
| **Pathway analyses fecal water samples** |
| **Fecal metabolites** |  | **Metabolites** | ***P*** | **Holm *P*** | **FDR** | **Impact** |
| AP | Valine, leucine and isoleucine biosynthesis | Leucine, valine | 8.25 × 10-4 | 0.069 | 0.069 | 0.0 |
|  | Aminoacyl-tRNA biosynthesis | Valine, leucine, tyrosine | 0.002 | 0.17 | 0.08 | 0.0 |
|  | Valine, leucine and isoleucine degradation | Leucine, valine | 0.02 | 1 | 0.48 | 0.0 |
|  | Phenylalanine, tyrosine and tryptophan biosynthesis | Tyrosine | 0.02 | 1 | 0.48 | 0.5 |
| CRC | Aminoacyl-tRNA biosynthesis | Phenylalanine, valine, leucine, tyrosine | 2.3 × 10-4 | 0.019 | 0.01 | 0 |
|  | Phenylalanine, tyrosine and tryptophan biosynthesis | Phenylalanine, tyrosine | 2.7 × 10-4 | 0.022 | 0.035 | 1 |
|  | Valine, leucine and isoleucine biosynthesis | Leucine, valine | 0.0012 | 0.1 | 0.035 | 0.0 |
|  | Phenylalanine metabolism | Phenylalanine, tyrosine | 0.0019 | 0.16 | 0.041 | 0.36 |
|  | Galactose metabolism | Galactose, glycerol | 0.014 | 1.0 | 0.2 | 0.05 |
|  | Valine, leucine and isoleucine degradation | Valine, leucine | 0.03 | 1.0 | 0.43 | 0.0 |

An integrated analysis based on MetaboAnalyst 4.0 software built on significantly altered metabolites in colorectal cancer (CRC); and adenomatous patients (AP): View of most contributing pathways; *P* is the original *P* value calculated from the enrichment analysis; Holm *P* is the *P* value adjusted by Holm-Bonferroni method; the false discovery rate is the *P* value adjusted using false discovery rate (FDR); Impact is the pathway impact value calculated from pathway topology analysis.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**